------------------------------ ---------------------
CUSIP NO. 543162101 SCHEDULE 13D PAGE 2 OF 13 PAGES
------------------------------ ---------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
ADVISORY RESEARCH, INC.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
OO
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
-0-
----------------------------------------------------------
NUMBER OF 8 SHARED VOTING POWER
SHARES
BENEFICIALLY 3,310,093
OWNED BY ----------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH -0-
----------------------------------------------------------
10 SHARED DISPOSITIVE POWER
3,310,093
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
3,310,093
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES*
[ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.2% (1)
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IA
--------------------------------------------------------------------------------
* SEE INSTRUCTIONS
(1) Based on 36,007,597 outstanding shares of the common stock of the Company,
as reported in the Company's Schedule 14D9, filed with the Securities and
Exchange Commission on August 18, 2008.
------------------------------ ---------------------
CUSIP NO. 543162101 SCHEDULE 13D PAGE 3 OF 13 PAGES
------------------------------ ---------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
ADVISORY RESEARCH SMALL CAP EQUITY FUND, L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
OO
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
ILLINOIS
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
-0-
----------------------------------------------------------
NUMBER OF 8 SHARED VOTING POWER
SHARES
BENEFICIALLY 78,338
OWNED BY ----------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH -0-
----------------------------------------------------------
10 SHARED DISPOSITIVE POWER
78,338
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
78,338
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES*
[ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.2% (2)
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN
--------------------------------------------------------------------------------
* SEE INSTRUCTIONS
(2) See footnote (1) above.
------------------------------ ---------------------
CUSIP NO. 543162101 SCHEDULE 13D PAGE 4 OF 13 PAGES
------------------------------ ---------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
ADVISORY RESEARCH SMALL MID CAP VALUE EQUITY FUND, L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
OO
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
ILLINOIS
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
-0-
----------------------------------------------------------
NUMBER OF 8 SHARED VOTING POWER
SHARES
BENEFICIALLY 59,300
OWNED BY ----------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH -0-
----------------------------------------------------------
10 SHARED DISPOSITIVE POWER
59,300
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
59,300
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES*
[ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.2% (3)
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN
--------------------------------------------------------------------------------
* SEE INSTRUCTIONS
(3) See footnote (1) above.
------------------------------ ---------------------
CUSIP NO. 543162101 SCHEDULE 13D PAGE 5 OF 13 PAGES
------------------------------ ---------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
ADVISORY RESEARCH SMALL CAP EQUITY FUND II, L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
OO
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
ILLINOIS
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
-0-
----------------------------------------------------------
NUMBER OF 8 SHARED VOTING POWER
SHARES
BENEFICIALLY 62,690
OWNED BY ----------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH -0-
----------------------------------------------------------
10 SHARED DISPOSITIVE POWER
62,690
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
62,690
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES*
[ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.2% (4)
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN
--------------------------------------------------------------------------------
* SEE INSTRUCTIONS
(4) See footnote (1) above.
------------------------------ ---------------------
CUSIP NO. 543162101 SCHEDULE 13D PAGE 6 OF 13 PAGES
------------------------------ ---------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
ADVISORY RESEARCH SMALL MID CAP VALUE EQUITY FUND II, L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
OO
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
ILLINOIS
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
-0-
----------------------------------------------------------
NUMBER OF 8 SHARED VOTING POWER
SHARES
BENEFICIALLY 130,030
OWNED BY ----------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH -0-
----------------------------------------------------------
10 SHARED DISPOSITIVE POWER
130,030
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
130,030
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES*
[ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.4% (5)
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN
--------------------------------------------------------------------------------
* SEE INSTRUCTIONS
(5) See footnote (1) above.
------------------------------ ---------------------
CUSIP NO. 543162101 SCHEDULE 13D PAGE 7 OF 13 PAGES
------------------------------ ---------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
ADVISORY RESEARCH ALL CAP FUND, L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
OO
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
ILLINOIS
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
-0-
----------------------------------------------------------
NUMBER OF 8 SHARED VOTING POWER
SHARES
BENEFICIALLY 8,650
OWNED BY ----------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH -0-
----------------------------------------------------------
10 SHARED DISPOSITIVE POWER
8,650
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
8,650
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES*
[ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.02% (6)
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN
--------------------------------------------------------------------------------
* SEE INSTRUCTIONS
(6) See footnote (1) above.
------------------------------ ---------------------
CUSIP NO. 543162101 SCHEDULE 13D PAGE 8 OF 13 PAGES
------------------------------ ---------------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
ADVISORY RESEARCH GLOBAL ALL CAP FUND, L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
OO
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
ILLINOIS
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
-0-
----------------------------------------------------------
NUMBER OF 8 SHARED VOTING POWER
SHARES
BENEFICIALLY 662
OWNED BY ----------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH -0-
----------------------------------------------------------
10 SHARED DISPOSITIVE POWER
662
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
662
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES*
[ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
Less than 0.01% (7)
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN
--------------------------------------------------------------------------------
* SEE INSTRUCTIONS
(7) See footnote (1) above.
------------------------------ ---------------------
CUSIP NO. 543162101 SCHEDULE 13D PAGE 9 OF 13 PAGES
------------------------------ ---------------------
ITEM 1. SECURITY AND ISSUER
The Schedule 13D filed on August 20, 2008 and amended on September 12,
2008 by Advisory Research, Inc. ("ARI"), a Delaware corporation, Advisory
Research Small Cap Equity Fund, L.P. ("Advisory Small Cap"), Advisory Research
Small Mid Cap Value Equity Fund, L.P. ("Advisory Small Mid Cap"), Advisory
Research Small Cap Equity Fund II, L.P. ("Advisory Small Cap II"), Advisory
Research Small Mid Cap Value Equity Fund II, L.P. ("Advisory Small Mid Cap II"),
Advisory Research All Cap Fund, L.P. ("Advisory All Cap"), and Advisory Research
Global All Cap Fund, L.P. ("Advisory Global All Cap") and along with ARI, the
"Reporting Persons", with respect to the common stock, par value $0.50 per
share (the "Common Stock") of Longs Drug Stores Corp. (the "Company"), Maryland
corporation, is hereby amended by this Amendment No. 2. Only those items hereby
reported in this Amendment No. 2 are amended and all other items remain
unchanged.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
Item 3. is hereby restated as follows:
Funds for the purchase of the Common Stock reported herein were
derived from available capital of the Advisory Small Cap, Advisory Small
Mid Cap, Advisory Small Cap II, Advisory Small Mid Cap II, Advisory All
Cap and Advisory Global All Cap funds as well as client funds of ARI.
A total of approximately $128.3 million was paid to acquire such Common
Stock.
ITEM 4. PURPOSE OF TRANSACTION.
Item 4 is hereby supplemented, as follows:
Reference is made to the Reporting Persons' Letter to Shareholders, dated
October 1, 2008, a copy of which is attached hereto as Exhibit D and is
incorporated herein by reference.
------------------------------ ---------------------
CUSIP NO. 543162101 SCHEDULE 13D PAGE 10 OF 13 PAGES
------------------------------ ---------------------
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
Paragraphs (a), (b) and (c) of Item 5 of the Schedule 13D are hereby
restated as follows:
(a) As of the close of business on September 30, 2008, ARI may be
deemed the beneficial owner of an aggregate of 3,310,093 shares of Common
Stock, constituting approximately 9.2% of the Common Stock outstanding.
Advisory Small Cap may be deemed the beneficial owner of 78,338 shares of
Common Stock, constituting approximately 0.2% of the Common Stock outstanding.
Advisory Small Mid Cap may be deemed the beneficial owner of 59,300 shares
of Common Stock, constituting approximately 0.2% of the Common Stock
outstanding. Advisory Small Cap II may be deemed the beneficial owner of
62,690 shares of Common Stock, constituting approximately 0.2% of the
Common Stock outstanding. Advisory Small Mid Cap II may be deemed the
beneficial owner of 130,030 shares of Common Stock, constituting
approximately 0.4% of the Common Stock outstanding. Advisory All Cap
may be deemed the beneficial owner of 8,650 shares of Common Stock,
constituting approximately 0.02% of the Common Stock outstanding.
Advisory Global All Cap may be deemed the beneficial owner of 911,969
shares of may be deemed the beneficial owner of 662 shares of Common
Stock, constituting approximately 0.00% of the Common Stock outstanding.
The aggregate percentage of shares of Common Stock beneficially
owned by the Reporting Persons is based upon 36,007,597 shares of Common
Stock outstanding, which is the total number of shares of Common Stock
outstanding as of August 14, 2008 as reported in the Company's Schedule
14D9 filed with the Securities and Exchange Commission on August 18, 2008.
(b) By virtue of investment management agreements with each of
Advisory Small Cap, Advisory Small Mid Cap, Advisory Small Cap II, Advisory
Small Mid Cap II, Advisory All Cap and Advisory Global All Cap, and other
discretionary client funds, ARI has the power to vote or direct the voting,
and to dispose or direct the disposition, of all of the 3,310,093 shares of
Common Stock held by ARI. Advisory Small Cap has the power to vote or direct
the voting, and to dispose or direct the disposition of all of the 78,338
shares of Common Stock it holds. Advisory Small Mid Cap has the power to
vote or direct the voting, and to dispose or direct the disposition of all
of the 59,300 shares of Common Stock it holds. Advisory Small Cap II has
the power to vote or direct the voting, and to dispose or direct the
disposition of all of the 62,690 shares of Common Stock it holds. Advisory
Small Mid Cap II has the power to vote or direct the voting, and to dispose
or direct the disposition of all of the 130,030 shares of Common Stock it
holds. Advisory All Cap has the power to vote or direct the voting, and
to dispose or direct the disposition of all of the 8,650 shares of Common
Stock it holds. Advisory Global All Cap has the power to vote or direct
the voting, and to dispose or direct the disposition of all of the 662
shares of Common Stock it holds. Accordingly, ARI is deemed to have shared
voting and shared dispositive power with respect to an aggregate of 3,310,093
shares of Common Stock.
(c) Information concerning transactions in the shares of Common Stock
effected by the Reporting Persons in since the most recent filing on Schedule
13D on September 12, 2008 is set forth in Schedule A hereto and is incorporated
herein by reference. Unless otherwise indicated, all of such transactions
were effected in the open market.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH
RESPECT TO SECURITIES OF THE ISSUER.
Except for ARI acting as investment advisor for its clients who own the
shares of Common Stock described herein, the Reporting Persons do not have any
contract, arrangement, understanding or relationship with any person with
respect to the securities of the Company.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
Exhibit D - Letter to the Board of Directors of Longs Drug Stores,
dated October 1, 2008.
--------------------------- -------------------
CUSIP NO. 543162101 SCHEDULE 13D PAGE 11 OF 13 PAGES
--------------------------- -------------------
SIGNATURES
After reasonable inquiry and to the best of his or its knowledge and
belief, the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Dated: October 1, 2008
ADVISORY RESEARCH, INC.
By: /s/ Brien M. O'Brien
---------------------------
Name: Brien M. O'Brien
Title: Chairman & CEO
ADVISORY RESEARCH SMALL CAP EQUITY FUND, L.P.
By: Advisory Research, Inc.,
General Partner
By: /s/ Brien M. O'Brien
---------------------------
Name: Brien M. O'Brien
Title: Chairman & CEO
ADVISORY RESEARCH SMALL MID CAP VALUE EQUITY
FUND, L.P.
By: Advisory Research, Inc.,
General Partner
By: /s/ Brien M. O'Brien
---------------------------
Name: Brien M. O'Brien
Title: Chairman & CEO
ADVISORY RESEARCH SMALL CAP EQUITY FUND II, L.P.
By: Advisory Research, Inc.,
General Partner
By: /s/ Brien M. O'Brien
---------------------------
Name: Brien M. O'Brien
Title: Chairman & CEO
ADVISORY RESEARCH SMALL MID CAP VALUE EQUITY
FUND II, L.P.
By: Advisory Research, Inc.,
General Partner
By: /s/ Brien M. O'Brien
---------------------------
Name: Brien M. O'Brien
Title: Chairman & CEO
ADVISORY RESEARCH ALL CAP FUND, L.P.
By: Advisory Research, Inc.,
General Partner
By: /s/ Brien M. O'Brien
---------------------------
Name: Brien M. O'Brien
Title: Chairman & CEO
ADVISORY RESEARCH GLOBAL ALL CAP FUND, L.P.
By: Advisory Research, Inc.,
General Partner
By: /s/ Brien M. O'Brien
---------------------------
Name: Brien M. O'Brien
Title: Chairman & CEO
--------------------------- -------------------
CUSIP NO. 543162101 SCHEDULE 13D PAGE 12 OF 13 PAGES
--------------------------- -------------------
EXHIBIT D
ADVISORY RESEARCH, INC.
180 North Stetson
Suite 5500
Chicago, IL 60601
October 1, 2008
Mr. Warren F. Bryant Dr. Mary S. Metz, Ph.D
Chairman and CEO Chairperson, Governance and
Longs Drug Stores Corp. Nominating Committee
141 N. Civic Dr. Longs Drug Stores Corp.
Walnut Creek, CA 94596 141 N. Civic Dr.
Walnut Creek, CA 94596
Dear Dr. Metz and Warren:
We have read with keen interest your announcement that the Federal Trade
Commission has served on Longs a 25 page request for documents and information
in connection with Walgreens' offer to purchase for $75 per share all of the
outstanding shares of Longs. It is now time for the Longs' Board to step up to
the plate and respond to the FTC's request thoroughly and expeditiously.
We have been extremely disappointed with the Board's failure, first, to
disclose critical information about Longs' real estate and lease holdings,
second, to engage in a fair and open auction process to sell the Company and,
third, to respond positively to Walgreens' $75 per share offer.
Your dismissive responses to the Walgreen's offer of considerably more money
than the CVS deal, stripped of its argumentative rhetoric, boils down to only
two issues, namely, can a Walgreens/Longs merger be accomplished under the
antitrust laws and, if so, how long will it take? The investigatory request
to Longs demonstrates that the FTC is engaged and that the Commission is
prepared to make a determination as to whether Walgreens can acquire Longs
and on what terms. This eliminates your first expressed concern and also
eliminates your posturing and reliance on legal advice which is no longer
persuasive in light of the FTC's review of the matter and the potential, if
not likelihood, that an agreement can be reached between the FTC and Walgreens
that will permit the acquisition to proceed.
As to your second concern about timing, here is where the Longs Board is
obligated to exercise its fiduciary duty to promptly and completely satisfy
the FTC's request. To do otherwise might impair Walgreens' ability to reach
an agreement with the FTC and proceed with its superior offer. This would
deprive Longs shareholders of the ability to take advantage of the clearly
higher offer of $75 per share from Walgreens in contrast to the CVS lower
offer of $71.50 per share. CVS has also publicly stated that it will stand
firm at this lower per share price.
As Longs' largest shareholder with holdings for our clients of approximately
9.2% of Longs' outstanding shares, we expect the Board to satisfy its
fiduciary duties to its shareowners by adopting a level playing field posture
and by fully cooperating with the FTC.
Very truly yours,
David B. Heller
President
DBH/tlc60678288
--------------------------- -------------------
CUSIP NO. 543162101 SCHEDULE 13D PAGE 13 OF 13 PAGES
--------------------------- -------------------
SCHEDULE A
Transactions in the shares by the Reporting Persons since September 12, 2008.
All of such transactions were effected in the open market. ARI effected its
transactions in its capacity as an investment manager on behalf of certain
managed accounts.
ADVISORY RESEARCH, INC.
Trade Date Shared Purchased (Sold) Price Per Share ($)
----------- ------------------------ -------------------
9/19/2008 (1200) $75.00
9/26/2008 (1724) $76.03
9/26/2008 (300) $76.00
9/29/2008 (1500) $75.48
ADVISORY RESEARCH SMALL CAP
Trade Date Shared Purchased (Sold) Price Per Share ($)
----------- ------------------------ -------------------
NONE
ADVISORY RESEARCH SMALL MID CAP
Trade Date Shared Purchased (Sold) Price Per Share ($)
----------- ------------------------ -------------------
NONE
ADVISORY RESEARCH SMALL CAP II
Trade Date Shared Purchased (Sold) Price Per Share ($)
----------- ------------------------ -------------------
NONE
ADVISORY RESEARCH SMALL MID CAP II
Trade Date Shared Purchased (Sold) Price Per Share ($)
----------- ------------------------ -------------------
NONE
ADVISORY RESEARCH ALL CAP
Trade Date Shared Purchased (Sold) Price Per Share ($)
----------- ------------------------ -------------------
NONE
ADVISORY RESEARCH GLOBAL ALL CAP
Trade Date Shared Purchased (Sold) Price Per Share ($)
----------- ------------------------ -------------------
NONE
|